The Miller Fisher variant is an uncommon but well known syndrome being described as a triad of areflexia, ataxia and complex ophthalmoplegia. It is characterized by antibodies against myelin that affects peripheral nerves, extraocular muscles and Schwann cells. Anti-ganglioside antibodies have been recognized in disease pathogenesis and decreasing antibody production is the mainstay of treatment. The course is usually benign with improvement after immunomodulation. This case report describes the approach to a patient suspected of having a demyelinating disorder. It delineates the subsets of immune mediated neuropathies in evaluating the diagnosis and emphasizes the need for early therapeutic intervention in achieving a good clinical outcome.
Introduction
Anti GQ1b antibodies target peripheral nerves, activate complement and cause conduction block. This leads to an immune mediated neuropathy affecting extraocular muscles. Miller Fisher syndrome (areflexia, ataxia and complex ophthalmoplegia) encompasses a spectrum of immune mediated motor and sensory neuropathies.
A 35-year-old female with a prior history of an upper respiratory tract infection presented with diplopia, bilateral orbital pain and headache. Clinical examination revealed an ataxic gait, areflexia and a complex ophthalmoplegia consistent with the clinical triad of Miller Fisher Syndrome.
The hallmark of this syndrome is the presence of anti GQ1b antibodies. This condition usually has an excellent prognosis with treatment as it usually follows an uncomplicated course without remissions. Treatment is based on reducing antibody levels.
Case Report
A 35-year-old woman presented with a two day history of diplopia, bi-frontal headache and bilateral orbital pain. Two weeks prior to these symptoms, she had a non-specific upper respiratory tract infection. There was no significant past medical history. Drug history included analgesics when necessary. The patient did not use alcohol, cigarettes or illicit drugs.
On examination she had a right sided ptosis and bilateral lateral rectus weakness. Other cranial nerves were normal. Diplopia was pronounced on bilateral horizontal gaze.
Tone and power were normal in the upper and lower limbs. Reflexes throughout were all absent and plantars were equivocal bilaterally. There was bilateral dysmetria but no dysdiadochokinesia. Gait was ataxic with inability to tandem walk. Position, vibration and pin prick sensation were all intact. Romberg's test was negative. Cardiovascular, respiratory and abdominal examinations were all unremarkable.
Investigations included the following: complete blood count, urea and electrolytes, liver enzymes and inflammatory markers were all within normal limits. The cerebrospinal fluid (CSF) protein was mildly elevated at 73 (12 -60) mg/dl. The fluid was acellular with a normal glucose level. Electromyography (EMG)/ nerve conduction study showed normal sensory action potentials. Small and splayed common peroneal compound muscle action potentials with normal nerve conduction velocities and normal F wave latencies were found. The findings were in keeping with bilateral common peroneal nerve dysfunction. Muscle sampling was normal. Computed Tomography (CT) brain (non contrast) was normal. Magnetic Resonance Imaging (MRI) brain non contrast was normal. Anti GQ1b Ig G was elevated, >1:100 (Negative-<1:100).
Treatment was initiated with intravenous Immunoglobulin (IVIG) 0.4 grams/ kilogram/day for 5 days. There was significant clinical improvement during the hospital stay. However at six weeks the patient still exhibited an ataxic gait and a further course of IVIG was given at 0.4 g/kilogram/day for 5 days. The patient showed further improvement and at three months was normal. She remains well two years on. Informed consent was obtained from this patient for reporting her case.
Discussion
The clinical triad of ophthalmoplegia, ataxia and areflexia is in keeping with the Miller Fisher Syndrome discovered in 1956 [1] . As the years progressed, new cases were reported and anti-ganglioside antibodies were recognized as a possible pathophysiologic process underlying the disease mechanism. Therapeutic measures targeted at this pathway proved to be successful in management.
The patient had a history of a recent viral infection and subsequently devel- Antibodies to GQ1b bind to human peripheral nerves; predominantly oculomotor nerves and exhibits the a-latrotoxin-like effects [3] . This involves complement activation targeting nerve terminal architecture and Schwann cells [4] [5] [6] [7] . GQ1b gangliosides can be found in the oculomotor, trochlear, and abducens nerves [8] . The development of complex ophthalmoplegia can be explained by this as antibodies binding to myelin provoke an immune response causing demyelination. Antibodies to GQ1b are most likely induced during the infection preceding the onset of neurological symptoms by the mechanism of molecular mimicry [9] .
Intravenous immunoglobulin preparations counteract these effects [10] 
